Strong Momentum in Pharma Commercialization

Houlihan Lokey is pleased to share its featured 2024 transactions in pharma commercialization, making it one of the most active advisors in the space.

We have been privileged to advise a number of clients along the drug development lifecycle, including medical affairs, market access, health economics, regulatory affairs, life sciences consulting, and data and technology.

Our continued activity in the sector has provided us with unparalleled industry observations, real-time insights, and unique perspectives on relevant investors. Should you be exploring opportunities in the market or considering alternatives, please feel free to reach out to our team.

Click on each transaction to learn more.

About Houlihan Lokey

Houlihan Lokey, Inc. (NYSE:HLI) is a global investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, and financial and valuation advisory. Houlihan Lokey serves corporations, institutions, and governments worldwide with offices in the Americas, Europe, the Middle East, and the Asia-Pacific region. Independent advice and intellectual rigor are hallmarks of the firm’s commitment to client success across its advisory services. The firm is the No. 1 investment bank for all global M&A transactions for the past two consecutive years, the No. 1 M&A advisor for the past 10 consecutive years in the U.S., the No. 1 global restructuring advisor for the past 11 consecutive years, and the No. 1 global M&A fairness opinion advisor over the past 25 years, all based on number of transactions and according to data provided by LSEG (formerly Refinitiv).